{
  "pmcid": "PMC2859392",
  "pmid": "20338069",
  "title": "Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults",
  "overall_score": 0.13934486309687297,
  "num_benchmarks": 4,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 0,
        "unmatched_count": 2,
        "items": [
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1448993666,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "Efficacy",
              "Significance": "no",
              "Notes": "No significant difference in median CD4 T cell counts of each genotype at different time points was seen in efavirenz group (p = 0.818, 0.838, 0.783, 0.753 and 0.587 for baseline, weeks 12, 24, 36 and 48 of ART, respectively).",
              "Sentence": "Genotype TT is not associated with response to efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "20338069",
              "Variant Annotation ID_norm": "1448993666"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1184988061,
              "Variant/Haplotypes": "rs3745274",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "Metabolism/PK",
              "Significance": "yes",
              "Notes": "Association with significantly increased efavirenz plasma levels. Was significant at week 6, 12 of treatment and 1 month after rifampicin discontinuation.",
              "Sentence": "Genotype TT is associated with decreased metabolism of efavirenz in people with HIV Infections and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "decreased",
              "PD/PK terms": "metabolism of",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:HIV infectious disease, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "20338069",
              "Variant Annotation ID_norm": "1184988061"
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 12,
        "items": [
          {
            "variant": "CYP2B6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In 65 HIV/TB adults on efavirenz plus rifampicin, mean 12-hour post-dose plasma efavirenz concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L in TT patients, 3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L in GT patients, and 2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L in GG patients; TT vs GT or GG p < 0.0001 at all three time points.",
              "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma efavirenz concentration in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "12-hour post-dose plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001).\"",
                "\"The results indicated that the wide interindividual variability of efavirenz concentrations is strongly influenced by CYP2B6-516TT genotype by the finding of significantly higher plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation compared to those with GT or GG genotype.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "G516T",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In 65 HIV/TB adults on efavirenz plus rifampicin, mean 12-hour post-dose plasma efavirenz concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L in TT patients, 3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L in GT patients, and 2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L in GG patients; TT vs GT or GG p < 0.0001 at all three time points.",
              "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma efavirenz concentration in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "12-hour post-dose plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"The mean 12-hour post-dose plasma efavirenz concentration in patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (10.97 \u00b1 2.32, 13.62 \u00b1 4.21 and 8.48 \u00b1 1.30 mg/L, respectively) were significantly higher than those with GT (3.43 \u00b1 0.29, 3.35 \u00b1 0.27 and 3.21 \u00b1 0.22 mg/L, respectively) (p < 0.0001) or GG genotypes (2.88 \u00b1 0.33, 2.45 \u00b1 0.26 and 2.08 \u00b1 0.16 mg/L, respectively) (p < 0.0001).\"",
                "\"The results indicated that the wide interindividual variability of efavirenz concentrations is strongly influenced by CYP2B6-516TT genotype by the finding of significantly higher plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation compared to those with GT or GG genotype.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In 59 HIV/TB adults on nevirapine plus rifampicin, mean 12-hour post-dose plasma nevirapine concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L in TT patients, 5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L in GT patients, and 5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L in GG patients; overall TT vs others showed a trend, with p = 0.003 at week 6 and p = 0.409 and 0.448 at weeks 12 and post-rifampicin, respectively.",
              "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma nevirapine concentration in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "12-hour post-dose plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Likewise, the mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those carrying GT (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotypes (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively).\"",
                "\"Similar results were found in nevirapine group (Figure [1d, e, f](#F1)) in that the mean plasma drug concentration of patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those with GT genotype (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotype (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively).\"",
                "\"CYP2B6-TT genotype had impact on plasma efavirenz and nevirapine concentrations, while rifampicin co-administration had only small effects.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "G516T",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "yes",
              "Notes": "In 59 HIV/TB adults on nevirapine plus rifampicin, mean 12-hour post-dose plasma nevirapine concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L in TT patients, 5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L in GT patients, and 5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L in GG patients; overall TT vs others showed a trend, with p = 0.003 at week 6 and p = 0.409 and 0.448 at weeks 12 and post-rifampicin, respectively.",
              "Sentence": "Genotype TT is associated with increased 12-hour post-dose plasma nevirapine concentration in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "12-hour post-dose plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Likewise, the mean 12-hour post-dose plasma nevirapine concentration in patients carrying TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those carrying GT (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotypes (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively).\"",
                "\"Similar results were found in nevirapine group (Figure [1d, e, f](#F1)) in that the mean plasma drug concentration of patients with TT genotype at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation (14.09 \u00b1 9.49, 7.94 \u00b1 2.76 and 9.44 \u00b1 0.17 mg/L, respectively) tended to be higher than those with GT genotype (5.65 \u00b1 0.54, 5.58 \u00b1 0.48 and 7.03 \u00b1 0.64 mg/L, respectively) or GG genotype (5.42 \u00b1 0.48, 5.34 \u00b1 0.50 and 6.43 \u00b1 0.64 mg/L, respectively) (p = 0.003, p = 0.409 and p = 0.448, respectively).\"",
                "\"CYP2B6-TT genotype had impact on plasma efavirenz and nevirapine concentrations, while rifampicin co-administration had only small effects.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "At week 12 of ART in the efavirenz group, 88.89% (8/9) of TT, 77.42% (24/31) of GT, and 68% (17/25) of GG patients achieved plasma HIV-1 RNA <50 copies/mL; p = 0.430 for comparison among genotypes.",
              "Sentence": "Genotype TT is not associated with response to efavirenz in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "As shown in Table [2](#T2), when the proportion of patients with HIV-1 RNA level <50 copies/mL (log 1.69) were compared among *CYP2B6*-G516T genotypes at week 12 of ART, 88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430).",
                "With respect to possible correlation of the variations in plasma efavirenz and nevirapine levels with the treatment outcome, our results indicated that the patients with *CYP2B6 *516TT genotype had a higher frequency of viral load suppression at week 12 of ART than those with GT and GG genotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "G516T",
            "gene": "CYP2B6",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "At week 12 of ART in the efavirenz group, 88.89% (8/9) of TT, 77.42% (24/31) of GT, and 68% (17/25) of GG patients achieved plasma HIV-1 RNA <50 copies/mL; p = 0.430 for comparison among genotypes.",
              "Sentence": "Genotype TT is not associated with response to efavirenz in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "As shown in Table [2](#T2), when the proportion of patients with HIV-1 RNA level <50 copies/mL (log 1.69) were compared among *CYP2B6*-G516T genotypes at week 12 of ART, 88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430).",
                "With respect to possible correlation of the variations in plasma efavirenz and nevirapine levels with the treatment outcome, our results indicated that the patients with *CYP2B6 *516TT genotype had a higher frequency of viral load suppression at week 12 of ART than those with GT and GG genotype."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2B6",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "CYP2B6",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "At week 12 of ART in the nevirapine group, 100% (2/2) of TT, 70.97% (23/31) of GT, and 60% (15/26) of GG patients achieved plasma HIV-1 RNA <50 copies/mL; p = 0.288 for comparison among genotypes.",
              "Sentence": "Genotype TT is not associated with response to nevirapine in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "As shown in Table [2](#T2), when the proportion of patients with HIV-1 RNA level <50 copies/mL (log 1.69) were compared among *CYP2B6*-G516T genotypes at week 12 of ART, 88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430). Similarly, in nevirapine group, 100% (2/2) of those with TT genotype, 70.97% (23/31) of those with GT genotype and 60% (15/26) of those with GG genotype could achieve the HIV-1 RNA levels <50 copies/mL, but this difference also did not reach statistical significance (p = 0.288) due to small numbers of patients with homozygous TT genotype in this study.",
                "Table 2 Caption: Number of patients with plasma HIV-1 RNA < 50 copies/ml at week 12 of ART."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "G516T",
            "gene": "CYP2B6",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "G516T",
              "Gene": "CYP2B6",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "efficacy",
              "Significance": "no",
              "Notes": "At week 12 of ART in the nevirapine group, 100% (2/2) of TT, 70.97% (23/31) of GT, and 60% (15/26) of GG patients achieved plasma HIV-1 RNA <50 copies/mL; p = 0.288 for comparison among genotypes.",
              "Sentence": "Genotype TT is not associated with response to nevirapine in patients with HIV infectious disease and Tuberculosis as compared to genotypes GG + GT.",
              "Alleles": "TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "response to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "GG + GT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "As shown in Table [2](#T2), when the proportion of patients with HIV-1 RNA level <50 copies/mL (log 1.69) were compared among *CYP2B6*-G516T genotypes at week 12 of ART, 88.89% (8/9) of patients with TT genotype in efavirenz group could achieve the HIV-1 RNA levels <50 copies/mL, which were higher than those with GT genotype (77.42%, 24/31) and GG genotype (68%, 17/25), although this difference was not statistically significant (p = 0.430). Similarly, in nevirapine group, 100% (2/2) of those with TT genotype, 70.97% (23/31) of those with GT genotype and 60% (15/26) of those with GG genotype could achieve the HIV-1 RNA levels <50 copies/mL, but this difference also did not reach statistical significance (p = 0.288) due to small numbers of patients with homozygous TT genotype in this study.",
                "Table 2 Caption: Number of patients with plasma HIV-1 RNA < 50 copies/ml at week 12 of ART."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs28399499",
                "variant_id": "PA166155478",
                "confidence": 0.8
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP3A4",
            "gene": "CYP3A4",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "CYP3A4",
              "Gene": "CYP3A4",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "not stated",
              "Notes": "In the efavirenz group, mean plasma efavirenz concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L in TT homozygotes (n=62) and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L in TC heterozygotes (n=3); authors noted a trend towards higher levels in TC, but did not perform formal statistical testing due to the small TC sample.",
              "Sentence": "Genotype TC is associated with increased plasma efavirenz concentration in patients with HIV infectious disease and Tuberculosis as compared to genotype TT, although statistical significance was not evaluated.",
              "Alleles": "TC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"With respect to *CYP3A4*, the analysis was done in only *CYP3A4-*T878C, since there was no variation at the *CYP3A4*-T878C and -C1088T in our study subjects. The results showed that the mean plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L, respectively, in patients with homozygous TT genotype and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L, respectively, in those with heterozygous TC genotype.\"",
                "\"Similarly, the mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype. Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP3A4 T878C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "T878C",
            "gene": "CYP3A4",
            "drug": "efavirenz",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "T878C",
              "Gene": "CYP3A4",
              "Drug(s)": "efavirenz",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "not stated",
              "Notes": "In the efavirenz group, mean plasma efavirenz concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L in TT homozygotes (n=62) and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L in TC heterozygotes (n=3); authors noted a trend towards higher levels in TC, but did not perform formal statistical testing due to the small TC sample.",
              "Sentence": "Genotype TC is associated with increased plasma efavirenz concentration in patients with HIV infectious disease and Tuberculosis as compared to genotype TT, although statistical significance was not evaluated.",
              "Alleles": "TC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"With respect to *CYP3A4*, the analysis was done in only *CYP3A4-*T878C, since there was no variation at the *CYP3A4*-T878C and -C1088T in our study subjects. The results showed that the mean plasma efavirenz concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 4.00 \u00b1 0.42, 4.20 \u00b1 0.72 and 3.48 \u00b1 0.34 mg/L, respectively, in patients with homozygous TT genotype and 9.62 \u00b1 6.35, 8.97 \u00b1 6.33 and 3.87 \u00b1 1.69 mg/L, respectively, in those with heterozygous TC genotype.\"",
                "\"Similarly, the mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype. Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP3A4 T878C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "efavirenz",
                "drug_id": "PA449441",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP3A4",
            "gene": "CYP3A4",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "CYP3A4",
              "Gene": "CYP3A4",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "not stated",
              "Notes": "In the nevirapine group, mean plasma nevirapine concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L in TT homozygotes (n=58); in a single TC heterozygote, values were 4.8, 8.69 and 9.12 mg/L at the corresponding time points. Authors reported a trend towards higher plasma drug levels in TC but did not perform statistical analysis due to n=1.",
              "Sentence": "Genotype TC is associated with increased plasma nevirapine concentration in patients with HIV infectious disease and Tuberculosis as compared to genotype TT, although statistical significance was not evaluated.",
              "Alleles": "TC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For CYP3A4-T878C, there were 95.4% (62/65) of homozygous TT and 4.6% (3/65) of heterozygous TC, and 98.3% (58/59) of homozygous TT and 1.69% (1/59) of heterozygous TC in efavirenz and nevirapine groups, respectively.\"",
                "\"Similarly, the mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype.\"",
                "\"Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP3A4 T878C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "T878C",
            "gene": "CYP3A4",
            "drug": "nevirapine",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "T878C",
              "Gene": "CYP3A4",
              "Drug(s)": "nevirapine",
              "PMID": 20338069,
              "Phenotype Category": "metabolism/PK",
              "Significance": "not stated",
              "Notes": "In the nevirapine group, mean plasma nevirapine concentrations at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L in TT homozygotes (n=58); in a single TC heterozygote, values were 4.8, 8.69 and 9.12 mg/L at the corresponding time points. Authors reported a trend towards higher plasma drug levels in TC but did not perform statistical analysis due to n=1.",
              "Sentence": "Genotype TC is associated with increased plasma nevirapine concentration in patients with HIV infectious disease and Tuberculosis as compared to genotype TT, although statistical significance was not evaluated.",
              "Alleles": "TC",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "plasma concentrations of",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:HIV Infections, Disease:Tuberculosis",
              "Multiple phenotypes or diseases And/or": "and",
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"For CYP3A4-T878C, there were 95.4% (62/65) of homozygous TT and 4.6% (3/65) of heterozygous TC, and 98.3% (58/59) of homozygous TT and 1.69% (1/59) of heterozygous TC in efavirenz and nevirapine groups, respectively.\"",
                "\"Similarly, the mean plasma nevirapine concentration at weeks 6 and 12 of ART and 1 month after rifampicin discontinuation were 5.85 \u00b1 0.48, 5.50 \u00b1 0.34 and 6.80 \u00b1 0.45 mg/L, respectively, in patients with homozygous TT genotype, and 4.8, 8.69 and 9.12 mg/L, respectively, in one patient with heterozygous mutant TC genotype.\"",
                "\"Although there was a trend towards higher plasma drug levels in patients with heterozygous mutant TC genotype, appropriate statistical evaluation of this difference was difficult due to small numbers of heterozygous mutant TC.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP3A4 T878C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "nevirapine",
                "drug_id": "PA450616",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "functional_analysis": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 0,
        "items": []
      }
    },
    "study_parameters": {
      "score": 0.6967243154843649,
      "total_samples": 2,
      "ground_truth_annotations": {
        "count": 2,
        "matched_count": 2,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.6441713220932904,
            "annotation": {
              "Study Parameters ID": 1184988079,
              "Variant Annotation ID": 1184988061,
              "Study Type": "cohort",
              "Study Cases": 65.0,
              "Study Controls": null,
              "Characteristics": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.62,
              "Allele Of Frequency In Cases": "G",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.0001",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1184988079,
                "prediction": 1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1184988061,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 65.0,
                "prediction": 65,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                "prediction": "Thai adults with HIV/TB coinfection receiving efavirenz-based ART plus rifampicin, CYP2B6 516TT vs GT vs GG and plasma efavirenz C12 at week 6",
                "score": 0.9509124755859375,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": 0.62,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "G",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "< 0.0001",
                "prediction": "< 0.0001",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5853421758202946,
            "annotation": {
              "Study Parameters ID": 1448993668,
              "Variant Annotation ID": 1448993666,
              "Study Type": "cohort",
              "Study Cases": 65.0,
              "Study Controls": null,
              "Characteristics": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.62,
              "Allele Of Frequency In Cases": "G",
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "> 0.05",
              "Ratio Stat Type": "OR",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1448993668,
                "prediction": 2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1448993666,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": "cohort",
                "prediction": "clinical trial",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 65.0,
                "prediction": 65,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "HIV-1/TB co-infected receiving efavirenz-based ART and an anti-TB drug regimen.",
                "prediction": "Thai adults with HIV/TB coinfection receiving efavirenz-based ART plus rifampicin, CYP2B6 516TT vs GT vs GG and plasma efavirenz C12 at week 12",
                "score": 0.9508169889450073,
                "match_status": "match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": 0.62,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": "G",
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "> 0.05",
                "prediction": "< 0.0001",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat Type": {
                "ground_truth": "OR",
                "prediction": "Unknown",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "East Asian",
                "prediction": "East Asian",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 8,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 3,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 65,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving efavirenz-based ART; comparison of plasma efavirenz C12 at week 6 vs 1 month after rifampicin discontinuation (overall, not stratified by genotype)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.043",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 4,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 65,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving efavirenz-based ART; comparison of plasma efavirenz C12 at week 12 vs 1 month after rifampicin discontinuation (overall, not stratified by genotype)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.133",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 59,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving nevirapine-based ART plus rifampicin, CYP2B6 516TT vs GT vs GG and plasma nevirapine C12 at week 6",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.003",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 59,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving nevirapine-based ART plus rifampicin, CYP2B6 516TT vs GT vs GG and plasma nevirapine C12 at week 12",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.409",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 59,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving nevirapine-based ART; comparison of plasma nevirapine C12 at week 6 vs 1 month after rifampicin discontinuation (overall, not stratified by genotype)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.034",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 59,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving nevirapine-based ART; comparison of plasma nevirapine C12 at week 12 vs 1 month after rifampicin discontinuation (overall, not stratified by genotype)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "< 0.001",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 65,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving efavirenz-based ART plus rifampicin; proportion with HIV-1 RNA <50 copies/mL at week 12 by CYP2B6 516 genotype (GG vs GT vs TT)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.68,
              "Allele Of Frequency In Cases": "HIV-1 RNA <50 copies/mL in CYP2B6 516GG",
              "Frequency In Controls": 0.889,
              "Allele Of Frequency In Controls": "HIV-1 RNA <50 copies/mL in CYP2B6 516TT",
              "P Value": "= 0.430",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 10,
              "Variant Annotation ID": null,
              "Study Type": "clinical trial",
              "Study Cases": 59,
              "Study Controls": null,
              "Characteristics": "Thai adults with HIV/TB coinfection receiving nevirapine-based ART plus rifampicin; proportion with HIV-1 RNA <50 copies/mL at week 12 by CYP2B6 516 genotype (GG vs GT vs TT)",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": 0.6,
              "Allele Of Frequency In Cases": "HIV-1 RNA <50 copies/mL in CYP2B6 516GG",
              "Frequency In Controls": 1.0,
              "Allele Of Frequency In Controls": "HIV-1 RNA <50 copies/mL in CYP2B6 516TT",
              "P Value": "= 0.288",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "East Asian",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}